Process / pipelineClinical / epidemiology

Pragmatic Phase IV Study — Real-World Post-Marketing Research

A pragmatic Phase IV study is a post-marketing investigation conducted under routine clinical conditions to evaluate a drug or device's real-world effectiveness, long-term safety, and comparative performance. Unlike the controlled Phase III environment, it intentionally minimizes protocol restrictions — broad eligibility criteria, standard-of-care comparators, and naturalistic follow-up — to generate evidence directly applicable to everyday clinical practice.

Open in MethodMindSoonVideoSoon

Read the full method

Members only

Sign in with a free account to read this section.

Sign in

Sources

  1. Thorpe, K. E., Zwarenstein, M., Oxman, A. D., Treweek, S., Furberg, C. D., Altman, D. G., ... & Chalkidou, K. (2009). A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. Journal of Clinical Epidemiology, 62(5), 464-475. DOI: 10.1016/j.jclinepi.2008.12.011
  2. Atkinson, M. J., & Lennox, R. D. (2012). Planning pragmatic clinical trials in Phase IV: pragmatic versus explanatory studies in post-marketing evaluation. Contemporary Clinical Trials, 33(2), 213-218. DOI: 10.1016/j.cct.2011.10.005

Related methods

Referenced by

ScholarGatePragmatic phase IV study (Pragmatic Phase IV Post-Marketing Study). Retrieved 2026-06-04 from https://scholargate.app/en/epidemiology/pragmatic-phase-iv-study